Antivirulence Compounds: A Future Direction to Overcome Antibiotic Resistance?
2020; Future Medicine; Volume: 15; Issue: 5 Linguagem: Inglês
10.2217/fmb-2019-0294
ISSN1746-0921
AutoresSilvia Buroni, Laurent R. Chiarelli,
Tópico(s)Antimicrobial Peptides and Activities
ResumoFuture MicrobiologyVol. 15, No. 5 EditorialAntivirulence compounds: a future direction to overcome antibiotic resistance?Silvia Buroni & Laurent R ChiarelliSilvia BuroniDepartment of Biology & Biotechnology 'Lazzaro Spallanzani', University of Pavia, Pavia, 27100, Italy & Laurent R Chiarelli *Author for correspondence: E-mail Address: laurent.chiarelli@unipv.ithttps://orcid.org/0000-0003-0348-9764Department of Biology & Biotechnology 'Lazzaro Spallanzani', University of Pavia, Pavia, 27100, ItalyPublished Online:14 Apr 2020https://doi.org/10.2217/fmb-2019-0294AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antibioticsantimicrobial resistanceantivirulence drugsdrug resistancequorum quenchingquorum sensingvirulence factorsReferences1. Review on Antimicrobial Resistance. http://www.amr-review.orgGoogle Scholar2. World Health Organization. Antimicrobial resistance. http://www.who.int/antimicrobial-resistance/publications/en/Google Scholar3. Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat. Rev. Drug. Discov. 16(7), 457–471 (2017).Crossref, Medline, CAS, Google Scholar4. D'Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 477(7365), 457–461 (2011).Crossref, Medline, Google Scholar5. von Wintersdorff CJ, Penders J, van Niekerk JM et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Front. Microbiol. 7, 173 (2016).Crossref, Medline, Google Scholar6. Czaplewski L, Bax R, Clokie M et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect. Dis. 16(2), 239–251 (2016).Crossref, Medline, CAS, Google Scholar7. Johnson BK, Abramovitch RB. Small molecules that sabotage bacterial virulence. Trends Pharmacol. Sci. 38(4), 339–362 (2017).Crossref, Medline, CAS, Google Scholar8. Meneghetti F, Villa S, Gelain A et al. Iron acquisition pathways as targets for antitubercular drugs. Curr. Med. Chem. 23(35), 4009–4026 (2016).Crossref, Medline, CAS, Google Scholar9. Butt AT, Thomas MS. Iron acquisition mechanisms and their role in the virulence of of Burkholderia species. Front. Cell. Infect. Microbiol. 7, 460 (2017).Crossref, Medline, Google Scholar10. Theuretzbacher U, Piddock LJV. Non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe 26(1), 61–72 (2019).Crossref, Medline, CAS, Google Scholar11. Defoirdt T. Quorum-sensing systems as targets for antivirulence therapy. Trends Microbiol. 26(4), 313–328 (2018).Crossref, Medline, CAS, Google Scholar12. Curtis MM, Russell R, Moreira CG et al. QseC inhibitors as an antivirulence approach for Gram-negative pathogens. MBio 5(6), e02165 (2014).Crossref, Medline, CAS, Google Scholar13. Mori M, Sammartino JC, Costantino L et al. An overview on the potential antimycobacterial agents targeting serine/threonine protein kinases from Mycobacterium tuberculosis. Curr. Top. Med. Chem. 19(9), 646–661 (2019).Crossref, Medline, CAS, Google Scholar14. Scoffone VC, Trespidi G, Chiarelli LR, Barbieri G, Buroni S. Quorum sensing as antivirulence target in cystic fibrosis pathogens. Int. J. Mol. Sci. 20(8), 1838 (2019).Crossref, CAS, Google Scholar15. Papenfort K, Bassler BL. Quorum sensing signal-response systems in Gram-negative bacteria. Nat. Rev. Microbiol. 14(9), 576–588 (2016).Crossref, Medline, CAS, Google Scholar16. Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Curr. Pharm. Des. 21(1), 5–11 (2015).Crossref, Medline, CAS, Google Scholar17. Sass A, Slachmuylders L, Van Acker H et al. Various evolutionary trajectories lead to loss of the tobramycin-potentiating activity of the quorum-sensing inhibitor baicalin hydrate in Burkholderia cenocepacia biofilms. Antimicrob. Agents Chemother. 63(4), e02092–18 (2019).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByMycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options27 February 2023 | International Journal of Molecular Sciences, Vol. 24, No. 5Virtual Screening and In Vitro Experimental Verification of LuxS Inhibitors for Escherichia coli O157:H721 February 2023 | Microbiology SpectrumN-Benzoylthiourea-pyrrolidine carboxylic acid derivatives bearing an imidazole moiety: Synthesis, characterization, crystal structure, in vitro ChEs inhibition, and antituberculosis, antibacterial, antifungal studiesJournal of Molecular Structure, Vol. 1273Targeting Siderophore-Mediated Iron Uptake in M. abscessus: A New Strategy to Limit the Virulence of Non-Tuberculous Mycobacteria2 February 2023 | Pharmaceutics, Vol. 15, No. 2Recent Strategies to Combat Multidrug Resistance14 February 2023Methyl 5-(2-Fluoro-4-nitrophenyl)furan-2-carboxylate12 November 2022 | Molbank, Vol. 2022, No. 45-(4-Nitrophenyl)furan-2-carboxylic Acid2 December 2022 | Molbank, Vol. 2022, No. 4The Role of MHC Class I and Class II Molecules in Antibacterial Immunity and Treatment of Bacterial Diseases18 November 2022 | Antibiotics and Chemotherapy, Vol. 67, No. 7-8Novel quorum sensing inhibitor Echinatin as an antibacterial synergist against Escherichia coli1 November 2022 | Frontiers in Microbiology, Vol. 13Novel Antibiofilm Inhibitor Ginkgetin as an Antibacterial Synergist against Escherichia coli8 August 2022 | International Journal of Molecular Sciences, Vol. 23, No. 15Antivirulence Agent as an Adjuvant of β-Lactam Antibiotics in Treating Staphylococcal Infections17 June 2022 | Antibiotics, Vol. 11, No. 6Scutellarin potentiates vancomycin against lethal pneumonia caused by methicillin-resistant Staphylococcus aureus through dual inhibition of sortase A and caseinolytic peptidase PBiochemical Pharmacology, Vol. 199The anti-virulence activity of the non-mevalonate pathway inhibitor FR900098 towards Burkholderia cenocepacia is maintained during experimental evolutionMicrobiology, Vol. 168, No. 3Targeting the Pseudomonas aeruginosa Virulence Factor Phospholipase C With Engineered Liposomes18 March 2022 | Frontiers in Microbiology, Vol. 13Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in mice21 January 2022 | The Journal of Antibiotics, Vol. 75, No. 3Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics4 February 2022 | Antibiotics, Vol. 11, No. 2Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discoveryEuropean Journal of Medicinal Chemistry, Vol. 224Taxifolin, an Inhibitor of Sortase A, Interferes With the Adhesion of Methicillin-Resistant Staphylococcal aureus6 July 2021 | Frontiers in Microbiology, Vol. 12Development and validation of a high-content screening assay for inhibitors of enteropathogenic E. coli adhesionJournal of Microbiological Methods, Vol. 184Myricetin as an Antivirulence Compound Interfering with a Morphological Transformation into Coccoid Forms and Potentiating Activity of Antibiotics against Helicobacter pylori7 March 2021 | International Journal of Molecular Sciences, Vol. 22, No. 5QseC Inhibition as a Novel Antivirulence Strategy for the Prevention of Acute Hepatopancreatic Necrosis Disease (AHPND)-Causing Vibrio parahaemolyticus21 January 2021 | Frontiers in Cellular and Infection Microbiology, Vol. 10Investigation of Virulence Genes Detected in Antimicrobial-Resistance Pathogens Isolates for Five Countries across the World2 December 2020 | Processes, Vol. 8, No. 12 Vol. 15, No. 5 Follow us on social media for the latest updates Metrics Downloaded 219 times History Received 24 October 2019 Accepted 14 February 2020 Published online 14 April 2020 Published in print March 2020 Information© 2020 Future Medicine LtdKeywordsantibioticsantimicrobial resistanceantivirulence drugsdrug resistancequorum quenchingquorum sensingvirulence factorsFinancial & competing interests disclosureFunding and support were provided by the Italian Ministry of Education, University and Research (MIUR): Dipartimenti di Eccellenza program (2018–2022) – Department of Biology and Biotechnology 'L Spallanzani', University of Pavia. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)